Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
View original at globenewswire.comPress Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patient…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Additional analyses of the PERIDOT data are ongoing with more information to be shared at a future medical meeting
80% confidenceVenglustat performed as well as ERT on non-neurological outcomes, including changes in spleen volume, liver volume, and hemoglobin levels
80% confidenceA daily pill could make a serious difference for Gaucher patients facing neurological challenges
80% confidenceVenglustat was well tolerated overall with no new safety signals compared with previous studies
80% confidenceCerezyme can now be prescribed globally to patients with either GD1 or GD3
80% confidenceSanofi will pursue global regulatory filings for venglustat in GD3
80% confidenceThere are no approved treatments for neurologic manifestations of GD3
80% confidenceThese findings underscore Sanofi's commitment to rare disease research and the promise we aim to deliver for people living with these conditions
80% confidence
Data points we hold from this source
| Sanofi · rare disease commitment | 40 years |